OBJECTIVE: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-years (95% CI 25.2-38.3): 23.7/1000 patient-years (95% CI 13.1-34.2) on ADA; 12.8/1000 patient-years (95% CI 6.3-19.4) on ETN and 65.1/1000 patient-years (95% CI 48.4-81.8) on IFN. The risk was higher in the first than in the second year of treatment, but this difference was not statistically significant (p=0.08) (38.9% of the SIs were recorded in the first 12months of treatment). The risk of SI was significantly different among the three treatment groups (p<0.0001). Multivariate models confirmed that the use of steroids (p<0.046), concomitant DMARD treatment during anti-TNF therapy (p=0.004), advanced age at the start of anti-TNF treatment (p<0.0001), and the use of IFN or ADA rather than ETN (respectively p<0.0001 and p=0.023) were strong and statistically significant predictors of infection. CONCLUSIONS: Anti-TNF therapy is associated with a small but significant risk of SI that is associated with the concomitant use of steroids, advanced age at the start of anti-TNF treatment, and the type of anti-TNF agent.
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry / Atzeni, F; Sarzi Puttini, P; Botsios, C; Carletto, A; Cipriani, P; Favalli, Eg; Frati, E; Foschi, V; Gasparini, S; Giardina, A; Gremese, E; Iannone, F; Sebastiani, Marco; Ziglioli, T; Biasi, D; Ferri, Clodoveo; Galeazzi, M; Gerli, R; Giacomelli, R; Gorla, R; Govoni, M; Lapadula, G; Marchesoni, A; Salaffi, F; Punzi, L; Triolo, G; Ferraccioli, G.. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - STAMPA. - 12(2012), pp. 225-229.
Data di pubblicazione: | 2012 |
Titolo: | Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. |
Autore/i: | Atzeni, F; Sarzi Puttini, P; Botsios, C; Carletto, A; Cipriani, P; Favalli, Eg; Frati, E; Foschi, V; Gasparini, S; Giardina, A; Gremese, E; Iannone, F; Sebastiani, Marco; Ziglioli, T; Biasi, D; Ferri, Clodoveo; Galeazzi, M; Gerli, R; Giacomelli, R; Gorla, R; Govoni, M; Lapadula, G; Marchesoni, A; Salaffi, F; Punzi, L; Triolo, G; Ferraccioli, G. |
Autore/i UNIMORE: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.autrev.2012.06.008 |
Rivista: | |
Volume: | 12 |
Pagina iniziale: | 225 |
Pagina finale: | 229 |
Codice identificativo ISI: | WOS:000313403500019 |
Codice identificativo Scopus: | 2-s2.0-84870253476 |
Codice identificativo Pubmed: | 22796281 |
Citazione: | Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry / Atzeni, F; Sarzi Puttini, P; Botsios, C; Carletto, A; Cipriani, P; Favalli, Eg; Frati, E; Foschi, V; Gasparini, S; Giardina, A; Gremese, E; Iannone, F; Sebastiani, Marco; Ziglioli, T; Biasi, D; Ferri, Clodoveo; Galeazzi, M; Gerli, R; Giacomelli, R; Gorla, R; Govoni, M; Lapadula, G; Marchesoni, A; Salaffi, F; Punzi, L; Triolo, G; Ferraccioli, G.. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - STAMPA. - 12(2012), pp. 225-229. |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
Long-term anti-TNF therapy and the risk of serious infections.pdf | Post-print dell'autore (bozza post referaggio) | Administrator Richiedi una copia |

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris